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Objective. The objective of this study was to evaluate the frequency and outcome of graft versus host disease after stem cell
transplantation for various haematological disorders in Pakistan.Materials and Methods. Pretransplant workup of the patient and
donor was performed. Mobilization was done with G-CSF 300 𝜇g twice daily for five day. Standard GvHD prophylaxis was done
with methotrexate 15mg/m2 on day +1 followed by 10mg/m2 on days +3 and +6 and cyclosporine. Grading was done according
to the Glucksberg classification. Results. A total of 153 transplants were done from April 2004 to December 2011. Out of these were
allogeneic transplants. There were females and males. The overall frequency of any degree of graft versus host disease was 34%.
Acute GvHD was present in patients while had chronic GvHD. Grade II GvHD was present in patients while grade III and IV
GvHD was seen in patients each. Acute myeloid leukemia and chronic myeloid leukemia were most commonly associated with
GvHD. The mortality in acute and chronic GvHD was 8.8% and 12% respectively. Conclusion. The frequency of graft versus host
disease in this study was 34% which is lower compared to international literature. The decreased incidence can be attributed to
reduced diversity of histocompatibility antigens in our population.
1. Introduction
Allogeneic haemopoietic stem cell transplant is an established
treatment modality for many malignant and non-malignant
conditions [1]. Its use over the last decade has exten-
sively expandedwhich includes nonmyeloablative transplant,
donor lymphocyte infusions, and umbilical cord blood trans-
plant [2, 3]. As the numbers of procedures continue to
increase with 25,000 transplants being performed annually,
the survival benefit, however, is complicated by graft versus
host disease (GvHD) leading to significantmorbidity,mortal-
ity, and limitation of its usage [4]. Most of the laboratories in
the world have adopted the high-resolution testing modality
for human leukocyte antigen (HLA) typing. Every condi-
tioning protocol incorporates the use of immunosuppres-
sion most commonly with cyclosporine and methotrexate.
Despite these measures, GvHD remains an important cause
of transplant-related mortality and morbidity leading to
limitation of its usage [5].
Approximately 30 years ago, the prerequisites of acute
GvHD were described by Billingham. These included
immunologically competent cells in sufficient numbers to be
present in the graft.The host to possess transplant isoantigens
not present in the graft and its immune system should
be incapable of mounting a reaction against the graft [6].
These immunologically competent T cells can cause GvHD
in various clinical scenarios when they are transfused from
blood products and solid organs to recipients who are unable
to mount an immune response against these cells. In the
early 1990s, based on Seattle experience, GvHD was defined
depending on the time at which it occurred; that is, early was
defined as occurring before 100 days and chronic occurring
after the defined period [7]. In 2005, the National Institutes
of Health Consensus included an entity of late onset acute
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GvHD (occurring after day 100) revealing features of both
acute and chronic GvHD [8].
Despite the 10/10 HLA antigen match using high-
resolution typing, approximately 30% of recipients of allo-
graft develop acute GvHD [9]. In 1990,Martin et al. described
acute graft versus host disease as involvement of skin which
is the most frequent organ involved (in 81%), gastrointestinal
tract in 54%, and liver in 50%of the patients [10].The extent of
involvement of these organs determines the severity of acute
GvHD.Overall grades are I (mild), II (moderate), III (severe),
and IV (very severe). The overall survival for grades III and
IV is very poor with 25% and 5% survival rates, respectively
[11].
ChronicGvHD is one of themain causes ofmorbidity and
mortality after stem cell transplant [12]. In Recipients who
have received 10/10 HLA-matched allografts, the incidence
has been estimated to range from 30 to 50% in long-term
survivors [13]. This incidence proportionately increases with
HLA disparity. Previously, chronic GvHD was classified as
“limited” versus “extensive”, and again in 2005, the new
staging system considered the number of organs involved
along with functional impairment [8]. Organ-specific scores
were assigned and overall stage was established as follows:
(1) mild chronic GvHD involves one or two sites (except
the lungs, which results in a classification of moderate
chronic GVHD at a minimum), with no clinically significant
functional impairment (maximum score of 2 in all affected
sites); (2) moderate chronic GVHD involves at least one
organ/site with clinically significant involvement but no
major functional disability (maximum score of 2 in any site)
orthree or more organs or sites with no clinically significant
functional impairment (max score of 1 in all organs/sites); (3)
severe chronic GVHD indicates major disability (score of 3 in
any organ/site) [14].
Graft versus host disease prophylaxis has been incorpo-
rated in every conditioning treatment protocol and it includes
cyclosporine on day 1 with serial monitoring of levels along
with administration of three doses of methotrexate [15].
In a developing country like Pakistan, stem cell transplant
is being performed in three centers throughout the country.
Our center was established in 2004. In this paper we present
the frequency and outcome of graft versus host disease in
allogeneic stem cell transplant over a period of six years at
our center. We have evaluated the distribution of haemato-
logical disordersmost commonly associated with graft versus
host disease; the outcome of patients and the comparative
differences in these variables between our population and
international literature have been elaborated.
2. Materials and Methods
All patients with nonmalignant and malignant haematologi-
cal disorders with HLA-matched donors were selected for the
procedure.
2.1. Pretransplant Workup. Complete blood counts, liver and
kidney function tests, and infectious disease profile (con-
sisting of hepatitis B surface antigen, hepatitis C antibody,
HIV antibody, cytomegalovirus, Mantoux test, and chest X
ray) along with blood grouping and coagulation testing were
performed in all donors. For patients, screening included
all the aforementioned investigations along with pulmonary
function tests, echocardiography, and dental evaluation.
2.2. Stem Cell Mobilization. All donors were given granulo-
cyte-colony stimulating factor (G-CSF) at a dose of 5𝜇g/kg
twice daily for five days prior to harvest. Patients with donors
less than five years received bonemarrow only as the stem cell
source. In patients with aplastic anaemia, peripheral blood
and bone marrow stem cells were the preferred source. In all
other conditions, peripheral blood progenitor cells only were
used as the source of stem cells.
2.3. Conditioning Regimen. Patients with thalassemia, acute
myeloid leukemia, chronic myeloid leukemia, biphenotypic
leukemia, and Philadelphia-negative, acute lymphoblastic
leukemia received Busulfan (1mg/kg/day q6 hours for four
days) and cyclophosphamide (60mg/kg/day for two days)
as conditioning chemotherapy. Class III thalassemic patients
received conditioning with hyperchelation protocol [16].
Total body irradiation (1.5cGYx twice a day for four days) and
Cyclophosphamide (60mg/kg/day for two days) were used
in patients with Philadelphia-positive acute lymphoblastic
leukemia and those with one-antigen mismatch donors (𝑛 =
6).
In aplastic anaemia, antithymocyte globulin (10mg/kg/
day for three days) and Cyclophosphamide (50mg/kg/day
for four days) were used. Patients with Fanconi’s anaemia
received conditioning with fludarabine (30mg/kg/day for
three days).
2.4. Infectious Disease Prophylaxis. Patients were admitted
in protective isolation equipped with HEPA filter, positive
pressure, and laminar airflow ventilation. Standard prophy-
laxis with ciprofloxacin (500mg twice daily or 20–30mg/
kg/two divided doses), fluconazole (200mg once daily or
6mg/kg/day), and valaciclovir (500mg twice daily or 10mg/
kg/twice daily) was started in all patients on day 5. All patients
were provided with neutropenic diet.
2.5. Graft versus Host Disease Prophylaxis. Intravenous Cy-
closporine was started on day 1 and doses were adjusted
according to drug levels. Optimum adult range was 200–
250 ng/dL. For paediatric patients, levels were maintained
between 150 and 200 ng/dL. Methotrexate 15mg/m2 was
administered on day +1, while 10mg/m2 was given on days
+3 and +6. Irradiated and leukocyte-reduced blood products
were used throughout admission as well as in the posttrans-
plant period. Clinical grading for acute GVHD was adapted
from Przepiorka et al. [17]. For chronic GVHD, criteria
defined by Shulman et al. were used [7].
2.6. Statistical Analysis. All data was entered on SPSS version
19 (SPSS Inc., Chicago, IL, USA) for computing means,
standard deviation, and range of all descriptive variables.
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Figure 1: Acute GvHD grade and organ of involvement (𝑛 = 19/34).
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Figure 2: Chronic GvHD grade and organ of involvement (𝑛 = 15/34).
3. Results
A total of stem cell transplants were performed from April
2004 to December 2011. Out of these 𝑛 = 101 were allogeneic
transplant procedures andwere autologous. Allogeneic trans-
plants were done for aplastic anaemia (𝑛 = 36), thalassemia
major (𝑛 = 21), chronic myeloid leukemia (𝑛 = 11), acute
myeloid leukemia (𝑛 = 10), acute lymphoblastic leukemia
(𝑛 = 8), myelodysplastic syndrome (𝑛 = 6), Fanconi’s
anaemia (𝑛 = 5), and 𝑛 = 1 each for haemophagocytic lym-
phohistiocytosis, osteopetrosis, biphenotypic leukemia and
mantle cell lymphoma. There were 72 males and 29 females.
The median age ± SD was 18 ± 12.4 years (range: 2–54
years). Four patients received stem cells from HLA-matched
parents. Five patients received stem cells from one HLA
antigen mismatch sibling donors. One patient received stem
cells from oneHLA antigenmismatch parent. Approximately
30% (𝑛 = 32) of the transplants were gender mismatched.
There were 7 male patients who received stem cells from
female donors previously sensitized by pregnancy.
The overall frequency of graft versus host disease was 34%
(𝑛 = 34). Acute GvHDwas present in 19 patients while 15 had
chronic GvHD. According to age groups, 7 pediatric patients
developed GvHD while 27 were adults (Table 1). The mean
mononuclear stem cell count (MNC) was 7.7 × 108/kg, and
Table 1: Frequency of GvHD according to age groups.
Age group Total (𝑛) GvHD (𝑛)
Yes No
Pediatric 44 7 37
Adult 57 27 30
Total 101 34 67
the mean CD34+ stem cell dose was 5.5 × 106/kg. Grade II
acute GvHD was present in 10 patients (52.6%), while grade
III and, IV was seen in 3 patients each. The most common
site of involvement in acute GvHD was skin and gut (𝑛 =
8) followed by skin only in 6 patients (Figure 1). Out of 15
patients with chronic GvHD, 13 had extensive involvement
(Figure 2). The most common site of involvement was skin
(𝑛 = 8) followed by liver (𝑛 = 3).
The most common haematological disorders associated
with GvHD were acute myeloid leukemia (70%) followed
by chronic myeloid leukemia (63%) and acute lymphoblastic
leukemia (50%); see Table 2. Out of 17 patients who received
“bone marrow only” as a source of stem cells, none of them
developed acute or chronic GvHD. For patients who received
peripheral blood only, out of 52, 15 (29%) developed acute
GvHD whereas 14 (27%) developed chronic GvHD. There
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Table 2: Frequency of GvHD according to haematological diseases.
Diagnosis GvHD 𝑛 (%) Total numberof cases
𝛽-Thalassemia major 5 21
Aplastic anaemia 5 36
Acute myeloid leukemia 7 10
Acute lymphoblastic leukemia 4 08
Chronic myeloid leukemia 7 11
Myelodysplastic syndrome 4 06
Biphenotypic leukemia 1 01
Osteopetrosis 1 01
HLH 0 01
Fanconi’s anaemia 0 05
Mantle cell lymphoma 0 01
Total 34 101
were 32 patients who received peripheral blood and bone
marrow as a combined source of stem cells. The frequency
of acute GvHD in this group was 12.5% (𝑛 = 4) and that of
chronic GvHD was 3.1% (𝑛 = 1).
Biopsy was performed in 32/34 patients and GvHD was
diagnosed in 84%of the cases. Death due to acute and chronic
GvHD was seen in 3 (8.8%) and 4 (12%), respectively.
4. Discussion
Development of graft versus host disease is generally consid-
ered to harbor the beneficial effect of graft versus leukemia
effect. However, in majority of patients it remains to be the
single determinant of long-term survival and quality of life
after bonemarrow transplant. Despite contemporary prophy-
laxis with cyclosporine, methotrexate, and irradiated blood
products, GvHD develops in 50% of the patients receiving
allografts. Depletion of T cells from donor can result in
controlling GvHD but in turn may lead to increased rates
of graft failure, impaired immune reconstitution, infections,
relapse, and posttransplant lymphoproliferative disorder [18,
19]. Apart from genetic factors, other causes of eliciting a
graft versus host response include donor type, haemopoietic
stem cell dose, and multiparous female donors [20]. In our
study, all seven male patients who received stem cells from
multiparous donors developed GvHD. In 2011, Flowers et al.
[21] reported an increased risk of grade 2–4 acute GvHD
when a female donor was used in a male recipient. Similar
results in children have been reported by Kondo et al. in 2011
[22]. One of the male patients in our study was three years
old with thalassemia major who received peripheral blood
stem cells from his mother and developed chronic extensive
GvHD.
In recipients of complete match sibling allografts, the
incidence of acute GvHD ranges from 35% to 45%. This
incidence increases with the amount of HLA disparity and
has been reported as high as 60% to 80% in recipients of
one antigen mismatch allografts [23, 24]. In our study, the
incidence of acute graft versus host diseasewas approximately
19%. This frequency is relatively lower when compared to
local data and studies done within the region byHashmi et al.
[25] and Ghavamzadeh et al. [26], respectively. Furthermore,
acute GvHDwas more frequently seen in adults as compared
to pediatric patients in our study. The incidence has been
reported as 60.2% by Liu et al. [27], and 29% by Shaw et al.
[28] and our frequency is lower to the figure quoted in both
studies done in pediatric cohort. With the rise in number
of allogeneic stem cell transplants, advances in pretrans-
plant conditioning regimens, and posttransplant care, the
incidence of chronic GvHD has also increased in long-term
survivors. In recipients of HLA-matched sibling donors, the
incidence of chronic GvHD has been reported as 30%–50%.
Sorror et al. [29] have reported cumulative incidence of
42% at 2 years in patients with advanced haematological
malignancies. Cantu-Rodriguez et al. reported an incidence
of 29.9% [30]. Both of these figures are in sharp contrast to the
frequency seen in our patients which was approximately 15%.
Our cohort mainly consisted of benign haematological disor-
ders like aplastic anaemia and beta thalassemia major which
prompted us to use either bonemarrow only or bonemarrow
and peripheral blood as a source of stem cells. This could be
one of the reasons behind the lower frequency in our study
since none of the patients whose stem cells were from bone
marrow developed GvHD. Secondly, since graft versus host
disease after stem cell transplant between siblings matched
for major histocompatibility complex develops presumably
as a result of differences in the minor histocompatibility
antigens between the donor and recipients, hypothetically
thismaymean that the degree ofHLApolymorphism is lower
in Pakistani population when compared with western cohort.
A graft versus leukemia effect can be obtained by
transfusion-induced suppression of host’s hematopoiesis
resulting from sharing of histocompatibility antigens with
the leukemia. In order to achieve this effect, we used
growth factor-stimulated peripheral blood only as a source
of stem cells in acute and chronic leukemia. Due to this,
the most common haematological disorders associated with
graft versus host disease were acute and chronic leukemia.
A meta-analysis done by Chang et al. [31] also identified the
aforementioned three most common haematological disor-
ders associated with GvHD. Recently, peripheral blood stem
cells have gained acceptance they and in 71% of allogeneic
transplants, are being used as stem cell source. Several
randomized studies have reported faster hematopoietic and
immune recovery. A retrospective study in 329 patients
comparing bone marrow and peripheral blood stem cells
showed a cumulative acute GvHD incidence of 51% and
54% in the bone marrow and peripheral blood stem cells
(PRBSCT) group, respectively [32]. The incidence of chronic
GvHD was 48% in patients who received PRBSCT. Although
our incidence is much lower from this cohort, interestingly,
none of the patients in groupwho received bonemarrow only
stem cells went on to develop acute or chronic GvHD. Our
center currently does not use T-cell-depleted PBSCT. This
could be one of the reasons for the striking difference in our
results of GvHD between the two stem cell sources.
In patients with acute GvHD, the transplant-related mor-
tality significantly increased and it correlated with the grade
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and organ of involvement. The EBMT group has reported a
mortality incidence of 25% in patientswithGvHD[33]. In our
study, mortality due to acute and chronic GvHD was 9% and
12%, respectively, which is much lower than that quoted in
the international literature. Reasons could be due to younger
age group of patients receiving allografts from young sibling
donors and low occurrence of grade III-IV GvHD eventually
leading to much lower frequency of chronic GvHD.
5. Conclusion
The incidence of acute and chronic GvHD in this study was
lower as compared to the international literature. Overall
frequency was 34%. Mortality due to acute and chronic
GvHD was 8.8% and 12%, respectively. GvHD developed
mainly in patients receiving peripheral blood stem cells. The
decreased incidence of GvHD can be due to reduced disparity
of histocompatibility antigens in our population.
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